References
- Kovachev SM. A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients. Infect Drug Resist. 2021, 14:2039-2049. doi: 10.2147/IDR.S296709
- Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019, 36(8):18781905. doi: 10.1007/s12325-019-00995-6999
- Beran J, Špajdel M, Slíva J. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease. Viruses. 2021, 13:2246. doi.org/10.3390/v13112246
- Jayanthi CR, Swain AK, Ganga RT, et al. Effcacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial. Adv Ther (Weinh). 2022, 2200159. doi: 10.1002/adtp.202200159
- Chen M, Zhang Y, Que XT, et al. Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers by hyphenated HPLC and tandem MS techniques. J Pharm Anal. 2013, 3(6):387-393. doi: 10.1016/j.jpha.2013.03.001.
- Gordon P, inventor, Newport Pharmaceuticals, Inc., assignee. Inosine derivatives. United States patent US, 1974, 3857940
- Perrie Y, Badhan RK, Kirby DJ, et al. The impact of ageing on the barriers to drug delivery. J Control Release. 2012, 161(2):389-98. doi: 10.1016/j.jconrel.2012.01.020.
- European Medicines Agency (2023a) List of nationally authorized medicinal products, Active substance: inosine dimepranol acedoben. EMA/179176/2019. Available from: https://riodic_safety_update_report_single_assessments.xlsx Accessed 9 Jul 2023.
- European Pharmacopoeia (Ph. Eur.) 10th ed. European Directorate for the Quality of Medicines & HealthCare. 2019, Available from: https://www.edqm.eu/en/. Accessed 9 Jul 2023.
- Lahane SH. Optimization of roll compactor variables and formulation of anti-retroviral tablet by roll compaction method. Int J Pharm Sci. 2020, 12(1): 48-53.
- European Medicines Agency (2023b) Stability testing of new drug substances and products. CPMP/ICH/2736/99. Available from: testing-new-drug-substances-drug-products-scientific-guideline. Accessed 11 Jul 2023.
- Kafedjiiski K. Formulation and in vitro evaluation of inosine acedoben dimepranol tablets. Pharmacia, 2022, 69(2): 319-325. doi: 10.3897/pharmacia.69.e81442.
- European Medicines Agency (2010) Guideline on the investigation of bioequivalence. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/Corr**. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 11 Jul 2023.
- Saharan VA, Kukkar V, Kataria M, et al. Ordered mixing: mechanism, process and applications in pharmaceutical formulations. Asian Journal of Pharmaceutical Sciences. 2008, 3(6): 240-259.
- Saint-Lorant G, Leterme P, Gayot A, Flament MP. Influence of carrier on the performance of dry powder inhalers. International Journal of Pharmaceutics. 2007, 334:85-91. doi: 10.1016/j.ijpharm.2006.10.028.
- Alen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems, 2001, 9th ed. Baltimore.
- Al-Zoubi N, Gharaibeh S, Aljaberi A, Nikolakakis I. Spray Drying for Direct Compression of Pharmaceuticals. Processes. 2021, 9(2): 267. doi: 10.3390/pr9020267.
- Kaye BH. Mixing of Powders. In: Fayed ME, Otten L, editors. Handbook of Powder Science & Technology. Springer New York, NY. 1997, pp. 568-585. doi: 10.1007/978-1-4615-6373-0.